Literature DB >> 18398752

Acute myeloid leukemia in Jehovah Witnesses.

Nicole M Brown, Gina Keck, Patricia A Ford.   

Abstract

Entities:  

Mesh:

Year:  2008        PMID: 18398752     DOI: 10.1080/10428190801911670

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


× No keyword cloud information.
  5 in total

1.  Bloodless cancer treatment results of patients who do not want blood transfusion: single center experience of 77 cases.

Authors:  Sung Yong Oh; Sung-Hyun Kim; Hyuk-Chan Kwon; Suee Lee; Kyeong Hee Kim; Kyung A Kwon; Jong-Hwan Lee; Kyu-Yeol Lee; Hyo-Jin Kim
Journal:  Support Care Cancer       Date:  2009-10-20       Impact factor: 3.603

2.  Induction with azacytidine followed by allogeneic hematopoietic stem cell transplantation in a Jehovah's Witness with acute monocytic leukemia.

Authors:  Hege Garelius; Sofia Grund; Dick Stockelberg
Journal:  Clin Case Rep       Date:  2015-02-13

3.  A Jehovah's Witness with Acute Myeloid Leukemia Successfully Treated with an Epigenetic Drug, Azacitidine: A Clue for Development of Anti-AML Therapy Requiring Minimum Blood Transfusions.

Authors:  Yumi Yamamoto; Akihito Kawashima; Eri Kashiwagi; Kiyoyuki Ogata
Journal:  Case Rep Hematol       Date:  2014-10-02

4.  A clinical challenge: Treatment of acute myeloid leukemia in a Jehovah's Witness.

Authors:  Daniela Cárdenas-Araujo; Elías Eugenio González-López; Xitlaly Judith González-Leal; José Carlos Jaime-Pérez; David Gómez-Almaguer
Journal:  Rev Bras Hematol Hemoter       Date:  2016-06-04

5.  Minimally-Myelosuppressive Asparaginase-Containing Induction Regimen for Treatment of a Jehovah's Witness with mutant IDH1/NPM1/NRAS Acute Myeloid Leukemia.

Authors:  Ashkan Emadi; Najeebah A Bade; Brandi Stevenson; Zeba Singh
Journal:  Pharmaceuticals (Basel)       Date:  2016-03-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.